CTTH · Ctt Pharmaceutical Holdings, Inc.
$0.06
0.00 (-0.17%)
At close · Oct 16
Return incl. dividend (before tax)
Going-concern doubt
— flagged Sep 17, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date of issuance of the audited financial statements.”View the 10-Q filed Sep 17, 2026
Market Cap
$3.52M
Shares
59.72M
Volume · Oct 16
2999
Avg daily vol (3M)
43.28K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.06
Open$0.05
Day$0.05–0.06
52W close$0.04–0.10
Avg vol 30d29K
Short int18K · 0.0% float · 1.0d
Short vol33%
DataJan 2020–Oct 2026
Filing10-Q · Sep 17
Up next
filed Sep 17, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$1.67M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
2.0
Trailing earnings · reciprocal yield 50.9%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$31
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+35.2%
Year over year · more shares
Price change (1Y)
-29.3%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−11%
below
Price vs 50-day avg
+4%
above
RSI (14)
59
neutral
MACD trend
Positive
52-week position
32%
mid-range
Volume (OBV)
Bearish div.
distributing
Momentum
relative strength
1-month return
+21%
trailing
6-month return
−20%
trailing
YTD return
−2%
this year
Relative strength
−27%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Accumulating
Net +$4.3K over 90 days · 0% sells
Short interest
Rising
0.03% of float · ▲ +75.6% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Squeeze score
29
low risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
166%
annualized · 1-yr
Max drawdown
−55%
past year
ATR
11.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−11%
Bearish
Price vs 50-day avg
+4%
Bullish
RSI (14)
59
Neutral
MACD trend
Positive
Bullish
52-week position
32%
Neutral
Volume (OBV)
Bearish div.
Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Accumulating
Net +$4.3K over 90 days · 0% sells
Short interest
Rising
0.03% of float · ▲ +75.6% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its 52-week range
Range low $0
Now $0 · 32%
Range high $0
vs 200-day avg -11%
vs 50-day avg +4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CTTH
this stock
Ctt Pharmaceutical Holdings, Inc.
|
$3.52M | -2.0% | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$62.65B | +28.8% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$48.90B | +1.1% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$48.14B | +30.9% | +4.3% | 67.7 | 2.6% |
|
HLN
Haleon plc
|
$44.59B | +0.6% | — | — | 0.6% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CTTH | +7.1% | +21.4% | -20.4% | +3.3% | -2.0% |
| SPY | -2.0% | +0.2% | +6.7% | +0.1% | +11.9% |
| vs SPY | +9.1% | +21.2% | -27.1% | +3.3% | -13.9% |